India, Sept. 30 -- The following biotech stocks reached a 52-week high on September 29, 2026, driven by key catalysts such as promising results from clinical trials or revised financial guidance.
Iovance Biotherapeutics Inc. (IOVA)
Iovance operates as a commercial-stage immune-oncology company, developing tumor infiltrating lymphocyte (TIL) therapies.The company saw shares surge over 31% to a new 52-week high of $11.17 in Tuesday's trade.
Among the products marketed by Iovance are Amtagvi, offered as a one-time treatment for advanced melanoma. Proleukin is also prescribed to treat metastatic renal cell carcinoma and metastatic melanoma.
On Tuesday, company raised its full year revenue guidance to range between $410 million and $420 mill...